{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["elritercept"]],"indication":null,"name":"ELRiSE MDS","nct_id":"NCT07422480","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elrise-mds-nct07422480. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELRiSE MDS","arms":[{"description":"Participants will receive elritercept at a starting dose of 3.75 milligrams per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks, and may have the dose escalated to 5.0 mg/kg if needed.","label":"Elritercept","type":"EXPERIMENTAL"},{"description":"Participants will receive epoetin alfa at a starting dose of 450 international units per kilograms (IU/kg) administered SC once every week, and may have the dose escalated up to 1050 IU/kg (maximum 80,000 IU).","label":"Epoetin Alfa","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2033-10-01","type":"ESTIMATED"},"conditions":["Myelodysplastic Syndrome","Anemia"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elritercept","otherNames":["TAK-226"],"type":"DRUG"},{"name":"Epoetin Alfa","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-06","lead_sponsor":"Takeda","official_title":"A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline","timeFrame":"From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)"}],"references":[],"start_date":{"date":"2026-05-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions","url":"https://clinicaltrials.gov/study/NCT07422480"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elrise-mds-nct07422480"}